Publicaciones en colaboración con investigadores/as de Toronto General Hospital (24)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2021

  1. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis

    Journal of the American College of Cardiology, Vol. 77, Núm. 12, pp. 1503-1516

  2. Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients

    American Journal of Transplantation, Vol. 21, Núm. 8, pp. 2709-2718

2019

  1. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  2. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort (Pediatr Nephrol, 10.1007/s00467-016-3469-3)

    Pediatric Nephrology

  2. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort

    Pediatric Nephrology, Vol. 32, Núm. 1, pp. 139-150

2015

  1. Consistency of benefit from an early invasive strategy after fibrinolysis: A patient-level meta-analysis

    Heart, Vol. 101, Núm. 19, pp. 1554-1561

  2. Role of atrial tissue remodeling on rotor dynamics: An in vitro study

    American Journal of Physiology - Heart and Circulatory Physiology, Vol. 309, Núm. 11, pp. H1964-H1973

  3. Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: A randomized clinical trial

    Transplantation, Vol. 99, Núm. 1, pp. 106-113

2014

  1. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

    Kidney International, Vol. 86, Núm. 4, pp. 828-836

2012

  1. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis

    Kidney International Supplements, Vol. 2, Núm. 2, pp. 139-274

2010

  1. Identifying predictors of central nervous system disease in solid organ transplant recipientswith cryptococcosis

    Transplantation, Vol. 89, Núm. 1, pp. 69-74

  2. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients

    Clinical Infectious Diseases, Vol. 51, Núm. 9, pp. 1062-1069

2009

  1. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis

    Clinical Infectious Diseases, Vol. 49, Núm. 11, pp. 1721-1728

2008

  1. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 2, pp. 735-738

  2. Central nervous system cryptococcosis in solid organ transplant recipients: Clinical relevance of abnormal neuroimaging findings

    Transplantation, Vol. 86, Núm. 5, pp. 647-651

  3. Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation

    Journal of Heart and Lung Transplantation, Vol. 27, Núm. 2, pp. 141-149

  4. Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen

    Clinical Infectious Diseases, Vol. 46, Núm. 2

2007

  1. Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality

    Journal of Infectious Diseases, Vol. 195, Núm. 5, pp. 756-764